Oppenheimer Assumes Cellectar Biosciences (CLRB) at Outperform

July 18, 2022 9:03 AM EDT Send to a Friend
Oppenheimer analyst Jeff Jones assumes coverage on Cellectar Biosciences (NASDAQ: CLRB) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login